

Gain-of-function mutations in protein kinase C α (PKC α) may promote synaptic defects in Alzheimer's disease

Stephanie I. Alfonso,^{1*} Julia A. Callender,^{2,3*} Basavaraj Hooli,^{4*} Corina E. Antal,^{2,3†} Kristina Mullin,⁴ Mathew A. Sherman,⁵ Sylvain E. Lesné,⁵ Michael Leitges,⁶ Alexandra C. Newton,^{2‡} Rudolph E. Tanzi,^{4‡} Roberto Malinow^{1‡}

Alzheimer's disease (AD) is a progressive dementia disorder characterized by synaptic degeneration and amyloid- β (A β) accumulation in the brain. Through whole-genome sequencing of 1345 individuals from 410 families with late-onset AD (LOAD), we identified three highly penetrant variants in *PRKCA*, the gene that encodes protein kinase C α (PKC α), in five of the families. All three variants linked with LOAD displayed increased catalytic activity relative to wild-type PKC α as assessed in live-cell imaging experiments using a genetically encoded PKC activity reporter. Deleting *PRKCA* in mice or adding PKC antagonists to mouse hippocampal slices infected with a virus expressing the A β precursor CT100 revealed that PKC α was required for the reduced synaptic activity caused by A β . In *PRKCA*^{-/-} neurons expressing CT100, introduction of PKC α , but not PKC α lacking a PDZ interaction moiety, rescued synaptic depression, suggesting that a scaffolding interaction bringing PKC α to the synapse is required for its mediation of the effects of A β . Thus, enhanced PKC α activity may contribute to AD, possibly by mediating the actions of A β on synapses. In contrast, reduced PKC α activity is implicated in cancer. Hence, these findings reinforce the importance of maintaining a careful balance in the activity of this enzyme.

INTRODUCTION

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive decline. Synaptic degeneration is among the earliest manifestations of AD in humans (1, 2) and is an early event in rodent models of AD (3–5). The loss of synapses may result from increased abundance of amyloid- β (A β) (6–8), a peptide that is associated with the development of AD (9). Familial forms of AD (hereditary early-onset AD), which account for less than 10% of AD cases, are caused by mutations in genes encoding amyloid precursor protein (APP) or β - and γ -secretases (enzymes that cleave APP) that result in increased abundance of the most toxic form of A β (9). The risk for late-onset AD (LOAD), which accounts for most AD cases, is increased in individuals expressing a variant of apolipoprotein E (APOE) called APOE- ϵ 4 (10), which may be less effective than other APOE alleles at promoting the removal of A β (9). Additional factors, such as innate immunity, namely, the AD-associated genes *CD33* and *TREM2*, also play a role (11, 12).

We sought to identify other genes that contribute to LOAD because their gene products may serve as therapeutic targets. We reasoned that variants of proteins participating in the detrimental effects of A β may contribute to the disease. We thus examined the signaling underlying A β -induced synaptic

depression. We focused on the multi-isozyme protein kinase C (PKC) family (13) because an interacting partner of the isozyme PKC α , PKC-binding protein (PICK1), is required for the synaptic effects of A β (14), and additionally, PKC α is required for a plasticity form of synaptic depression (15). The role of PKC isozymes in cancer is complex, but the finding that many cancer-associated mutations in PKC isozymes are actually loss of function indicates that reduced PKC activity contributes to increased cell survival (16). Therefore, we speculated that increased PKC activity could participate in the synaptic loss seen in AD.

RESULTS

PKC α is necessary for the synaptic effects of A β

To test whether the activity of PKC contributes to A β -induced synaptic depression, we added PKC antagonists to rodent organotypic hippocampal slices infected sparsely with a virus expressing CT100, which increases A β production by neurons (6, 8, 17). CT100 is the product of APP cleavage by β -secretase; CT100 is subsequently cleaved by γ -secretase to produce A β (18). After 16 to 24 hours, we evoked synaptic transmission by electrically stimulating presynaptic axons, and recordings were simultaneously obtained from neighboring infected and uninfected postsynaptic hippocampal CA1 neurons. Infected neurons (that expressed CT100) exhibited depressed excitatory transmission relative to that in uninfected neurons (Fig. 1A). Previous studies have shown that the effects of CT100 expression are due to the subsequent production of A β that induces the endocytosis of glutamate receptors and loss of synapses (6, 8, 17). To examine the role of PKC in A β -dependent synaptic depression, we incubated hippocampal slices (for ~12 hours before recordings) with the PKC inhibitors Gö 6983, an adenosine 5'-triphosphate (ATP) competitive inhibitor, or bisindolylmaleimide IV (Bis IV), an uncompetitive inhibitor; these inhibitors inhibit conventional (such as PKC α) and novel PKC isozymes. Synaptic depression by CT100

¹Department of Neurosciences and Division of Biology, Section of Neurobiology, University of California, San Diego, La Jolla, CA 92093, USA. ²Department of Pharmacology, University of California, San Diego, La Jolla, CA 92093, USA. ³Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA. ⁴Genetics and Aging Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA. ⁵Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55414, USA. ⁶Biotechnology Centre of Oslo, University of Oslo, Oslo 0317, Norway.

*These authors contributed equally to this work.

†Present address: Gene Expression Laboratory, Salk Institute, La Jolla, CA 92037, USA.

‡Corresponding author. Email: anewton@ucsd.edu (A.C.N.); tanzi@helix.mgh.harvard.edu (R.E.T.); rmalinow@ucsd.edu (R.M.).




Fig. 1. Synaptic depression by Aβ blocked by uncompetitive PKC antagonist. (A and B) Top left: Experimental design (see Materials and Methods). Plots (A) and bar graphs (B) of evoked synaptic response amplitudes recorded in CT100-infected versus noninfected neurons. Shown are individual (black) and average (red) of cell pair responses; sloped line, $x = y$. Sample traces (B, right) obtained from indicated conditions. Scale bars, 50 ms, 50 pA. Data are means \pm SEM from 12 to 13 pairs of cells (one infected, the other not); $**P < 0.03$, by bootstrap test (see Materials and Methods). (C) Normalized average of PKC activity in COS7 cells expressing PKC activity reporter CKAR (C kinase activity reporter) fused to PSD95 (left) or targeted to plasma membrane (right) in response to the competitive (Gö 6983) or uncompetitive (Bis IV) PKC inhibitor, added at the time indicated by the arrow head. Data are means \pm SEM from >16 cells; $****P < 0.0001$, by bootstrap test (see Materials and Methods); n.s., not significant.

expression was effectively blocked by Bis IV but not by Gö 6983 (Fig. 1, A and B). Because PKC is refractory to active-site inhibitors when it is bound to a scaffold protein near its substrates (19), these data suggest that scaffold protein-bound PKC may mediate the synaptic effects of Aβ. Of the PKC isozymes that are modulated by these inhibitors, only PKCα has a PDZ ligand, a three-amino acid segment at its C terminus that binds the PDZ domains of scaffolding proteins [notably PSD95, SAP97, and PICK1 (20, 21)]. Expression of CKAR, a genetically encoded fluorescence-based reporter of bulk PKC activity (22), in COS7 cells revealed that endogenous PKC activity at the PSD95 scaffold was effectively inhibited by Bis IV but not Gö 6983, whereas both inhibitors were equally effective at inhibiting bulk PKC activity measured at plasma membrane (Fig. 1C).

To test whether PKCα specifically mediates the synaptic effects of Aβ, organotypic hippocampal slices were prepared from wild-type mice and mice lacking PKCα (*PRKCA*^{-/-}) (23). Sixteen to 24 hours after infection, neurons expressing CT100 displayed depressed synaptic transmission compared to nearby neurons in slices from wild-type mice but showed no difference in *PRKCA*^{-/-} slices (Fig. 2, A and B). Western blot analysis revealed comparable levels of Aβ peptide in lysates from slices from *PRKCA*^{-/-} or wild-type animals infected with virus expressing CT100 (fig. S1). To determine whether absence of PKCα, rather than some developmental alteration in *PRKCA*^{-/-} mice, was responsible for the lack of effect by CT100 in neurons from *PRKCA*^{-/-} mice, we used a dual promoter virus to coexpress CT100 and PKCα in *PRKCA*^{-/-} organotypic slices. After expression, transmission onto infected neurons was depressed compared to noninfected neurons, indicating rescue of the effect of CT100 on synapses (Fig. 2A). To ensure the rescue of CT100-induced depression by PKCα coexpression was not due to potentiation of transmission by PKCα expression (which when added to the CT100-induced synaptic depression could normalize transmission), we coexpressed PKCα with CT84, the α-secretase product of APP that neither generates Aβ (18) nor causes synaptic depression (24). In this case, no significant potentiation was observed (Fig. 2A), indicating that PKCα coexpression rescued the effects of CT100 by enabling CT100-driven signaling. To test whether the effects of Aβ on synapses require that PKCα act at a scaffold, as suggested by the pharmacological results above, we coexpressed CT100 and a mutant form of PKCα that lacked the last three amino acids [PKCα (ΔPDZ)], which prevents its binding to PDZ domain proteins. In contrast to the coexpression of PKCα, coexpression of PKCα (ΔPDZ) did not rescue the effects of CT100 expression (Fig. 2A). These results indicate that PKCα, likely acting at a scaffold, is required for the depressive effects of Aβ on rodent synapses.

Whole-genome sequencing reveals PKCα variants in AD

To test whether PKCα plays a role in human AD, we searched whole-genome sequencing data for rare variants in *PRKCA* that were present in any of the 410 pedigrees from the National Institute of Mental Health (NIMH) Alzheimer's Disease Genetics Initiative (Fig. 3 and fig. S2). We identified three rare variants found in LOAD patients in these families. M489V [single nucleotide polymorphism: rs34406842; codon substitution: Atg/Gtg; minor allele frequency = 0.0005 in 1000 genomes of the general population (www.1000genomes.org)] was present in seven of nine affected individuals and was absent in the single unaffected subject in these four families. V636I (rs141376042; Gtc/Atc; minor allele frequency = 0.002 in 1000 genomes) was present in two of three affected subjects in one family in which no data from unaffected subjects were available. R324W (minor allele frequency = 0.00 in 1000 genomes) was present in one of two affected individuals and missing in the unaffected individual in a single LOAD pedigree. Thus, all individuals carrying a *PRKCA* variant developed AD, and all the individuals in these families who did not carry a *PRKCA* variant did not develop AD. Thus, the *PRKCA* variants identified in the NIMH data set appear to cosegregate with LOAD patients. A simple bootstrap test (see Materials and

Methods) suggests that the probability of finding such linkage in this population is less than 0.03.

AD-linked PKC α variants display increased cellular activity

Given that PKC α activity mediated the synaptic effects of increased abundance of A β (Figs. 1 and 2), we hypothesized that the rare PKC α variants




Fig. 2. PKC α is required for the effects of A β on synaptic transmission. (A and B) Plot (A), and example traces (bottom right), of evoked synaptic response amplitudes recorded in infected versus noninfected neurons; genotype and infection indicated. Bar graph (B, left) of same data. ** $P < 0.03$, by bootstrap test (see Materials and Methods). wt, wild-type.

found in LOAD families would have increased activity. This view is also suggested by the findings that reduced PKC function enhances survival in some cancer cells (16), whereas neuronal loss is seen in AD. Two of the rare variants observed in LOAD patients occur in key regulatory segments of the PKC family (13): M489V is in the activation loop near the entrance to the active site, and V636I is on the C-terminal segment that clamps over the kinase domain (Fig. 4A). Both segments interface with the Ca²⁺-sensing C2 domain, which maintains PKC α in an autoinhibited conformation (25). Thus, both mutations have the potential to destabilize autoinhibition. For example, molecular modeling reveals that replacement of the bulky Met at position 489 on the activation loop with the smaller Val loosens the packing of this key regulatory segment (Fig. 4A), consistent with reduced autoinhibition. Additionally, this residue is close to a segment in the kinase architecture, referred to as DFG +1, that is a key specificity determinant (26), and mutations in this region have been shown to alter substrate specificity in another PKC, PKC γ (27). The third variant, R324W, is also in a segment that controls autoinhibition; it is present in a flexible hinge, connecting the kinase domain with the regulatory moiety, that becomes exposed upon rupture of the C2-kinase domain contacts accompanying activation (25).

To examine the functional impact of amino acid changes, we assessed the effect of introducing these LOAD-associated rare variants on the function of PKC α . When expressed in COS7 cells, none of the three rare variants affected the phosphorylation of PKC α at priming sites that are indicative of proper protein folding (28), as assessed by Western blot analysis using phosphospecific antibodies (Fig. 4B). Further analysis of the M489V mutant revealed an increased rate of dephosphorylation after cells were stimulated with phorbol esters (Fig. 4C), potent activators that force PKCs into an open phosphatase-sensitive conformation (29). This enhanced rate of dephosphorylation supports the looser packing of the kinase domain resulting from replacement of Met with Val, favoring a more open (meaning active) conformation of the kinase when challenged with phorbol esters (30). The V636I mutant did not display the same enhanced rate of dephosphorylation, indicating that there may be other structural mechanisms through which this mutation destabilizes PKC autoinhibition.

To assess the effect of the amino acid changes on the signaling output of PKC α , we coexpressed PKC α variants or wild-type PKC α with cytosolic CKAR (22) in COS7 cells. All three rare variants showed enhanced agonist-evoked activity relative to wild-type PKC α (Fig. 5). This assay measures the phosphorylation of CKAR and reflects the allosteric activation of PKC induced by second messenger binding. This acute stimulation by natural agonists




Fig. 3. Human genetics of rare PKC α variants. Diagrams indicating number of families, along with phenotype and genotype of individuals, carrying M489V, V636I, or R324W PKC α variants. All PKC α variant carriers (yellow) displayed AD, and both individuals without AD (blue) lacked a PKC α variant.

does not cause the dephosphorylation or down-regulation of PKC that is caused by chronic activation by phorbol esters. These results indicate that all three rare PKC α variants found to cosegregate with LOAD display increased agonist-driven PKC α function.

DISCUSSION

AD is a lethal neurodegenerative disorder with increasing prevalence and no effective treatment (9). Elucidating the cellular signaling events that underlie the initiation and progression of LOAD can provide potential targets amenable to therapeutic intervention. Human genetic studies (31), particularly family-based studies (10) of rare variants (32), can identify potentially important molecules in LOAD. However, delineation of LOAD pathophysiology primarily from genetic information from smaller family studies remains challenging [see published comments and responses to (32)]. We therefore sought to combine a large genetic family study with neurophysiological and biochemical analyses to elucidate the signaling underlying LOAD pathophysiology.




Fig. 4. AD-associated rare variants in PKC α . (A) PKC α kinase domain structure (53) showing two residues altered in AD: Met⁴⁸⁹ and Val⁶³⁶. Both are near key regulatory phosphorylation sites (stick representation). Enlargement of activation loop segment (right panels) showing that substitution of Met⁴⁸⁹ with Val loosens the structural packing of this segment. (B) Western blot showing phosphorylation of the indicated hemagglutinin (HA)-tagged PKC α proteins. (C) Western blot of COS7 cells expressing wild-type or M489V PKC α and treated with phorbol 12,13-dibutyrate (PdBu) for the indicated times and probed for HA. Quantitative analysis of phosphorylated/total PKC from five independent experiments. ** $P < 0.01$, by bootstrap test (see Materials and Methods).

PKC α and AD pathophysiology

Although the cellular events that initiate LOAD remain unknown (9), increased accumulation of pathogenic forms of A β and the associated synaptic loss are strongly implicated in its early pathophysiology (1, 2, 33, 34). Various PKC isozymes have been implicated in AD in a number of studies (35–38). Supporting a role for enhanced signaling by PKC in AD, a recent phosphoproteomics study of postmortem brains identified increased phosphorylation of PKC substrates as a primary early event in AD (39). However, the role of PKC is not yet well understood. Understanding the biological functions of PKC in disease in general has presented a challenge given the presence of multiple isozymes and the opposing effects of phorbol esters in mediating short-term activation and long-term down-regulation. By combining the use of pharmacology, mouse genetics, and acute rescue experiments in this study, we can conclude the role of a specific PKC isozyme: our neurophysiological studies indicate that PKC α and its interaction with a protein through a PDZ domain interaction are required for A β to produce synaptic depression [consistent with a previous study demonstrating a requirement of PICK1 (14), a PDZ domain protein that binds PKC α]. Given the evidence supporting A β and synaptic loss in AD, our results suggest an important role for PKC α in AD.

Because conclusions regarding human disease based on physiology from immature rodent brain slices are tenuous, we turned to human genetics, which can provide insight into the function of aberrant PKC α signaling in disease. By scanning the genomes of individuals from a large LOAD family study, we identified three rare variants of PKC α that cosegregated with LOAD in six families. When examined in cell-based assays, all three variants displayed increased signaling output relative to wild-type PKC α . Notably, of the 46 PKC variants observed in cancers and tested for changed activity using the same assays, none displayed increased activity (16). Furthermore, the more strongly linked M489V mutation, found in seven of nine patients and not in an unaffected subject in four LOAD families, also elicited an enhanced rate of dephosphorylation after stimulation of cells with phorbol esters, consistent with a more open and signaling competent conformation. Thus, PKC α is required for deleterious synaptic effects of A β , observed early in LOAD, and increased PKC α activity can contribute to human LOAD.




Fig. 5. Live-cell imaging reveals higher signaling output of all three AD-associated rare variants. Left: Normalized FRET ratios (mean \pm SEM) representing PKC activity in COS7 cells coexpressing PKC activity reporter, CKAR, (22) and indicated PKC α . Addition of uridine 5'-triphosphate (UTP) (100 μ M) where indicated (arrow head). $n > 25$ cells for each construct. Data are means \pm SEM from at least three independent experiments. Right: Area under the curve from 3 to 6 min; * $P < 0.05$, by bootstrap test (see Materials and Methods). r.u., relative units.

PKC α activity: Increased in neurodegeneration and decreased in cancer

It is notable that we found activating PKC mutations in LOAD patients, whereas functional human cancer-associated PKC mutations are inactivating (16). The neurodegenerative disease, spinocerebellar ataxia, is caused by mutations in PKC γ that promote the open active conformation (40). Thus, our results are consistent with PKC gain-of-function mutations driving neurodegenerative diseases and loss-of-function mutations driving cell survival diseases. Supporting opposing roles of PKC in cancer versus AD, a recent meta-analysis of nine independent studies reveals that AD patients exhibit an overall 45% decreased risk of cancer compared with the general population (41), consistent with earlier reports that AD and cancer display an inverse association (42, 43). It is relevant that inhibitors of PKC have failed in cancer clinical trials (44), likely because PKC activity should be restored, rather than inhibited, in cancer therapy (16). In contrast, repurposing PKC inhibitors for LOAD may prevent the effects of A β on synapses and thereby mitigate loss of cognitive function. Together, our findings support inhibition of PKC α as a therapy early in LOAD and suggest that mutations in PKC α can serve as a diagnostic for disease susceptibility.

MATERIALS AND METHODS

Tissue preparation

Experiments were conducted in accordance with and received approval from the Institutional Animal Care and Use Committees at the University of California, San Diego. The experiments were carried out in accordance with guidelines laid down by the National Institutes of Health regarding the care and use of animals for experimental procedures.

Hippocampal slice cultures and Sindbis virus infection

Organotypic hippocampal slice cultures were made from postnatal day 6 or 7 rat pups as described (45). Slice cultures were maintained in culture for 6 to 8 days and then infected using a Sindbis virus (pSinRep5 dp APP-CT100 tdTomato). Cells were recorded 16 to 30 hours after infection. For Fig. 2 experiments, slices were made as described above, but from either wild-type or *PRKCA*^{-/-} mouse pups and infected with the indicated Sindbis viruses.

Electrophysiology and pharmacological treatments

Slices were maintained in a solution of artificial cerebrospinal fluid containing the following: 119 mM NaCl, 26 mM NaHCO₃, 1 mM NaH₂PO₄, 11 mM D-glucose, 2.5 mM KCl, 4 mM CaCl₂, 4 mM MgCl₂, and 1.25 mM NaHPO₄ and gassed with 95% O₂ 5% CO₂. In addition, the following drugs were included: 4 μ M 2-chloroadenosine (to prevent stimulus induced bursting) and 100 μ M picrotoxin (to block inhibitory transmission). For Figs. 1 and 2, simultaneous whole-cell recordings were obtained from pairs of neighboring (<50 μ m) control and infected CA1 pyramidal neurons using 3- to 5-megohm glass pipettes with an internal solution containing the following: 115 mM cesium methanesulfonate, 20 mM CsCl, 10 mM Hepes, 2.5 mM MgCl₂, 4 mM Na₂ATP, 0.4 mM Na₃GTP, 10 mM sodium phosphocreatine, 0.6 mM EGTA, and 0.1 mM spermine, at pH 7.25. All recordings were done by stimulating two independent synaptic inputs; EPSCs were recorded while holding the cells at -60 mV, alternating pathways every 8.4 s. Results from each pathway were averaged and counted as $n = 1$. For pharmacological experiments, slices were incubated overnight before recordings with either 0.3 μ M Gö 6983 or 3 μ M Bis IV; the drug was also added to the recording chamber at the same concentration. In addition, 10 μ M gabazine (to block inhibitory transmission) was added to the perfusion chamber. All data are reported as means \pm SEM. Statistical analysis used bootstrap (resampling) methods (46). For instance, in Fig. 1, we calculated the probability by bootstrap

resampling (100,000 times) the data from groups a = (CT100⁻, Gö 6983⁻, Bis IV⁻), b = (CT100⁺, Gö 6983⁻, Bis IV⁻), c = (CT100⁺, Gö 6983⁺, Bis IV⁻), and d = (CT100⁺, Gö 6983⁻, Bis IV⁺) and measuring the frequency with which A > C or B > C is true (where caps indicate mean); for Fig. 2, we bootstrap-resampled (100,000 times) data groups, measuring the frequency with which A > B or C > B or A > D is true. For Fig. 4, we bootstrap-resampled (100,000 times) data groups, measuring the frequency with which (MV at $t = 3$ hours > wild-type at $t = 3$ hours) or (MV at $t = 6$ hours > wild-type at $t = 6$ hours) is true.

Plasmid constructs

The CKAR and plasma membrane-localized PKC reporter were described previously (22). The PSD95-specific PKC reporter (PSD95-CKAR) contains CKAR with PSD95 fused to its N terminus via a four-amino acid linker (EPGQ) in a pcDNA3 vector (Life Technologies). PKC constructs were prepared as described previously (16). For HA-PKC α , human PKC α was N-terminally HA-tagged via Gateway cloning into pDEST-HA generated from ligating the reading frame cassette C into the EcoRV site of pcDNA3-HA. All mutants were generated using QuikChange site-directed mutagenesis (Agilent Technologies).

Antibodies and reagents

The pan antibody against the phosphorylated PKC activation loop (pT497) was previously described (47). The antibody to phosphorylated PKC α / β II (pT638/641; 9375S) and pan antibody to the phosphorylated PKC hydrophobic motif (β II pS660; 9371S) were purchased from Cell Signaling Technology. The α -HA antibody (anti-HA; 11867423001, clone 3F10) was purchased from Roche. PDBu, UTP trisodium salt, Gö 6983, and Bis IV were obtained from Calbiochem.

Cell culture, transfection, and immunoblotting

All cells were maintained in Dulbecco's modified Eagle's medium (Corning) containing 10% fetal bovine serum (Atlanta Biologicals) and 1% penicillin/streptomycin (Corning) at 37°C, in 5% CO₂. Transient transfection of COS7 was carried out using FuGENE 6 transfection reagent (Roche) for ~24 hours. Cells were lysed in 50 mM Tris (pH 7.4), 1% Triton X-100, 50 mM NaF, 10 mM Na₄P₂O₇, 100 mM NaCl, 5 mM EDTA, 1 mM Na₃VO₄, 1 mM phenylmethylsulfonyl fluoride, leupeptin (50 μ g/ml), 1 μ M microcystin, 1 mM dithiothreitol, and 2 mM benzamide. For PKC immunoblotting, whole-cell lysates were analyzed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting via chemiluminescence on a FluorChem Q imaging system (ProteinSimple). For cellular dephosphorylation experiments, cells were treated with 200 nM PDBu for the indicated times at 37°C before lysis. For A β immunoblotting, 10 μ g of protein per sample was electrophoresed on 10 to 20% SDS-polyacrylamide tris-tricine gels (Bio-Rad). Proteins were transferred to nitrocellulose, and membranes were boiled in phosphate-buffered saline for 5 min. Membranes were blocked in TBST (tris-buffered saline-Tween 20) containing 5% bovine serum albumin (#A3803, Sigma; >98% grade) for 1 hour at room temperature and probed with biotinylated 6E10 (BioLegend; 1:2500) or APPCter (#A8717, Sigma; 1:5000) in blocking solution. Primary antibodies were detected using anti-immunoglobulin G conjugated with either biotin or infrared dyes (LI-COR Biosciences). When biotin-conjugated antibodies were used, DyLight 800-conjugated NeutrAvidin (#22853, Thermo Scientific) was added to amplify the signal. Blots were imaged with an Odyssey detection system (LI-COR Biosciences).

Immunoprecipitation

Protein extract (200 μ g) was diluted to 1 ml with dilution buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl] and incubated with 25 μ l of MagG beads (Roche) cross-linked with 5 μ g of 4G8 overnight at 4°C. The following day, immune complexes were briefly washed with immunoprecipitation buffers

A and B for 5 min (48). The beads were then washed twice in 1 ml of dilution buffer, and proteins were eluted by boiling in 20 μ l of SDS-PAGE loading buffer.

FRET imaging and analysis

Cells were imaged as described previously (49). COS7 cells were cotransfected with the indicated mCherry-tagged PKC and either CKAR, plasma membrane-targeted CKAR, or PSD95-CKAR, as specified. Cells were rinsed once with and imaged in Hanks' balanced salt solution containing 1 mM CaCl₂. Images were acquired on a Zeiss Axiovert microscope (Carl Zeiss Microimaging Inc.) using a MicroMax digital camera (Roper-Princeton Instruments) controlled by MetaFluor software (Universal Imaging Corp.). Using a 10% neutral density filter, cyan fluorescent protein, yellow fluorescent protein (YFP), fluorescence resonance energy transfer (FRET), and mCherry images were obtained every 15 s. YFP emission was monitored as a control for photobleaching, and mCherry was measured to ensure that overexpressed PKC levels were equal in all experiments. Baseline images were acquired for ≥ 2 min before ligand addition, and data were normalized to the baseline FRET ratios. The normalized average FRET ratio is the average of these normalized values \pm SE. Area under the curve from 3 to 6 min was quantified and plotted in the bar graph in Fig. 5, and statistical significance was determined as indicated above.

Three-dimensional PKC structure modeling: The PKC α structure was visualized using the PyMOL Molecular Graphics System (version 1.7.4.1, Schrödinger LLC).

Genetics, family cohort

The NIMH Alzheimer's Disease Genetics Initiative Study (50), originally ascertained for the study of genetic risk factors in AD with family-based methods, was used in the whole-genome shotgun (WGS) analyses in this study. The basis for ascertainment in the NIMH collection was the existence of at least two affected individuals within a family, typically siblings. The complete NIMH study cohort contains a total of 1536 subjects from 457 families. For the purpose of this analysis, only subjects of self-reported European ancestry were included, consisting of 1376 participants (941 definitely affected and 404 definitely unaffected, and the remainder could not be determined as definitely unaffected or definitely affected) from 410 families.

To test the likelihood of finding the observed linkage in the mutant carrier families by chance, we conducted the following bootstrap analysis. We generated a "parent" set containing 941 ones (indicating affected) and 404 zeros (indicating unaffected), which is the nature of the definitely assessed population in this cohort. We wished to test the likelihood that choosing a set of 16 individuals (based on being in a family with a mutant protein) would show the observed linkage, that is, the likelihood that in choosing 10 individuals (variant carriers) all would have AD, and that in choosing 6 individuals (variant noncarriers) at least 2 would not have AD. We conducted the following sampling (allowing resampling) procedure: we chose 10 and 6 elements from the parent set to generate two subsets, y(1) and y(2). We then tested if all values in y(1) were 1 (test 1) and at least two values in y(2) were 0 (test2). If both tests were true, the result of the procedure was 1 (meaning chance could account for observed linkage); if any of the tests was false, the result of the procedure was 0. This procedure was conducted 100,000 times (run four times). The number of times the result of the procedure was 1 in the four runs was 2750, 2809, 2920, and 2861. Thus (dividing these values by 100,000), the likelihood of finding the observed linkage distribution by chance in this population is <0.03 .

Standard protocol approvals, registrations, and patient consents

Diagnosis of AD dementia was established according to NINCDA-ADRDA criteria. Informed consent was provided by all participants, and research ap-

proval was established by the relevant institutional review boards in the study cohort.

WGS data generation

Three micrograms of total genomic DNA (150 ng/ μ l) obtained from Rutgers repository was sequenced at Illumina Inc. using their latest HiSeq 2500 paired-end sequencing platform. An average of 48 \times coverage of 98% of the genome was observed in the resulting 120-gigabyte data from each sample. Genomic variants were called in-house using FreeBayes (v0.9.9.2-18) and GATK best practices method (51), resulting in close to 400 terabytes of high-quality sequencing data in a fully annotated GEMINI database (52).

SUPPLEMENTARY MATERIALS

www.sciencesignaling.org/cgi/content/full/9/427/ra47/DC1

Fig. S1. A β abundance in brain slices infected with virus producing CT100 is similar in wild-type and *PRKCA*^{-/-} slices.

Fig. S2. Pedigree charts of the NIMH families found to carry rare PKC α variants.

REFERENCES AND NOTES

1. R. D. Terry, E. Masliah, D. P. Salmon, N. Butters, R. DeTeresa, R. Hill, L. A. Hansen, R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. *Ann. Neurol.* **30**, 572–580 (1991).
2. D. J. Selkoe, Alzheimer's disease is a synaptic failure. *Science* **298**, 789–791 (2002).
3. A. Y. Hsia, E. Masliah, L. McConlogue, G.-Q. Yu, G. Tatsuno, K. Hu, D. Kholodenko, R. C. Malenka, R. A. Nicoll, L. Mucke, Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 3228–3233 (1999).
4. L. Mucke, E. Masliah, G.-Q. Yu, M. Mallory, E. M. Rockenstein, G. Tatsuno, K. Hu, D. Kholodenko, K. Johnson-Wood, L. McConlogue, High-level neuronal expression of A β _{1–42} in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. *J. Neurosci.* **20**, 4050–4058 (2000).
5. S. Oddo, A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kaye, R. Metherate, M. P. Mattson, Y. Akbari, F. M. LaFerla, Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A β and synaptic dysfunction. *Neuron* **39**, 409–421 (2003).
6. F. Kamenetz, T. Tomita, H. Hsieh, G. Seabrook, D. Borchelt, T. Iwatsubo, S. Sisodia, R. Malinow, APP processing and synaptic function. *Neuron* **37**, 925–937 (2003).
7. K. C. Wilcox, P. N. Lacor, J. Pitt, W. L. Klein, A β oligomer-induced synapse degeneration in Alzheimer's disease. *Cell. Mol. Neurobiol.* **31**, 939–948 (2011).
8. H. Hsieh, J. Boehm, C. Sato, T. Iwatsubo, T. Tomita, S. Sisodia, R. Malinow, AMPAR removal underlies A β -induced synaptic depression and dendritic spine loss. *Neuron* **52**, 831–843 (2006).
9. D. M. Holtzman, E. Mandelkow, D. J. Selkoe, Alzheimer disease in 2020. *Cold Spring Harb. Perspect. Med.* **2**, a011585 (2012).
10. E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921–923 (1993).
11. S. W. Pimplikar, R. A. Nixon, N. K. Robakis, J. Shen, L.-H. Tsai, Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. *J. Neurosci.* **30**, 14946–14954 (2010).
12. J. Shen, Function and dysfunction of presenilin. *Neurodegener. Dis.* **13**, 61–63 (2014).
13. A. C. Newton, Protein kinase C: Poised to signal. *Am. J. Physiol. Endocrinol. Metab.* **298**, E395–E402 (2010).
14. S. Alfonso, H. W. Kessels, C. C. Banos, T. R. Chan, E. T. Lin, G. Kumaravel, R. H. Scannevin, K. J. Rhodes, R. Haganir, K. M. Guckian, A. W. Dunah, R. Malinow, Synapto-depressive effects of amyloid beta require PICK1. *Eur. J. Neurosci.* **39**, 1225–1233 (2014).
15. M. Leitges, J. Kovac, M. Plomann, D. J. Linden, A unique PDZ ligand in PKC α confers induction of cerebellar long-term synaptic depression. *Neuron* **44**, 585–594 (2004).
16. C. E. Antal, A. M. Hudson, E. Kang, C. Zanca, C. Wirth, N. L. Stephenson, E. W. Trotter, L. L. Gallegos, C. J. Miller, F. B. Furnari, T. Hunter, J. Brognard, A. C. Newton, Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. *Cell* **160**, 489–502 (2015).
17. W. Wei, L. N. Nguyen, H. W. Kessels, H. Hagiwara, S. Sisodia, R. Malinow, Amyloid beta from axons and dendrites reduces local spine number and plasticity. *Nat. Neurosci.* **13**, 190–196 (2010).
18. C. Haass, C. Kaether, G. Thinakaran, S. Sisodia, Trafficking and proteolytic processing of APP. *Cold Spring Harb. Perspect. Med.* **2**, a006270 (2012).
19. N. Hoshi, L. K. Langeberg, C. M. Gould, A. C. Newton, J. D. Scott, Interaction with AKAP79 modifies the cellular pharmacology of PKC. *Mol. Cell* **37**, 541–550 (2010).

20. A. K. O'Neill, L. L. Gallegos, V. Justilien, E. L. Garcia, M. Leitges, A. P. Fields, R. A. Hall, A. C. Newton, Protein kinase C α promotes cell migration through a PDZ-dependent interaction with its novel substrate discs large homolog 1 (DLG1). *J. Biol. Chem.* **286**, 43559–43568 (2011).
21. J. Staudinger, J. Lu, E. N. Olson, Specific interaction of the PDZ domain protein PICK1 with the COOH terminus of protein kinase C- α . *J. Biol. Chem.* **272**, 32019–32024 (1997).
22. J. D. Violin, J. Zhang, R. Y. Tsien, A. C. Newton, A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C. *J. Cell Biol.* **161**, 899–909 (2003).
23. M. Leitges, M. Plomann, M. L. Standaert, G. Bandyopadhyay, M. P. Sajan, Y. Kanoh, R. V. Farese, Knockout of PKC α enhances insulin signaling through PI3K. *Mol. Endocrinol.* **16**, 847–858 (2002).
24. H. W. Kessels, S. Nabavi, R. Malinow, Metabotropic NMDA receptor function is required for β -amyloid-induced synaptic depression. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 4033–4038 (2013).
25. C. E. Antal, J. A. Callender, A. P. Kornev, S. S. Taylor, A. C. Newton, Intramolecular C2 domain-mediated autoinhibition of protein kinase C β II. *Cell Rep.* **12**, 1252–1260 (2015).
26. C. Chen, B. H. Ha, A. F. Thévenin, H. J. Lou, R. Zhang, K. Y. Yip, J. R. Peterson, M. Gerstein, P. M. Kim, P. Filippakopoulos, S. Knapp, T. J. Boggon, B. E. Turk, Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. *Mol. Cell* **53**, 140–147 (2014).
27. P. Creixell, E. M. Schoof, C. D. Simpson, J. Longden, C. J. Miller, H. J. Lou, L. Perryman, T. R. Cox, N. Zivanovic, A. Palmeri, A. Wesolowska-Andersen, M. Helmer-Citterich, J. Ferkinghoff-Borg, H. Itamochi, B. Bodenmiller, J. T. Erler, B. E. Turk, R. Lindig, Kinome-wide decoding of network-attacking mutations rewiring cancer signaling. *Cell* **163**, 1–16 (2015).
28. L. M. Keranen, E. M. Dutil, A. C. Newton, Protein kinase C is regulated in vivo by three functionally distinct phosphorylations. *Curr. Biol.* **5**, 1394–1403 (1995).
29. E. M. Dutil, L. M. Keranen, A. A. DePaoli-Roach, A. C. Newton, In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation. *J. Biol. Chem.* **269**, 29359–29362 (1994).
30. C. E. Antal, J. D. Violin, M. T. Kunkel, S. Skovsø, A. C. Newton, Intramolecular conformational changes optimize protein kinase C signaling. *Chem. Biol.* **21**, 459–469 (2014).
31. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, E. Majounie, C. Cruchaga, C. Sassi, J. S. K. Kauwe, S. Younkin, L. Hazrati, J. Collinge, J. Pocock, T. Lashley, J. Williams, J.-C. Lambert, P. Amouyel, A. Goate, R. Rademakers, K. Morgan, J. Powell, P. St. George-Hyslop, A. Singleton, J. Hardy, Alzheimer Genetic Analysis Group, *TREM2* variants in Alzheimer's disease. *N. Engl. J. Med.* **368**, 117–127 (2013).
32. C. Cruchaga, C. M. Karch, S. C. Jin, B. A. Benitez, Y. Cai, R. Guerreiro, O. Harari, J. Norton, J. Budde, S. Bertelsen, A. T. Jeng, B. Cooper, T. Skorupa, D. Carrell, D. Levitch, S. Hsu, J. Choi, M. Rytén; UK Brain Expression Consortium (UKBEC), C. Sassi, J. Bras, J. R. Gibbs, D. G. Hernandez, M. K. Lupton, J. Powell, P. Forabosco, P. G. Ridge, C. D. Corcoran, J. T. Schanz, M. C. Norton, R. G. Munger, C. Schmutz, M. Leary, F. Y. Demirci, M. N. Bamne, X. Wang, O. L. Lopez, M. Ganguli, C. Medway, J. Turton, J. Lord, A. Braae, I. Barber, K. Brown; Alzheimer's Research UK (ARUK) Consortium, P. Pastor, O. Lorenzo-Betancor, Z. Brkanac, E. Scott, E. Topol, K. Morgan, E. Rogaeva, A. B. Singleton, J. Hardy, M. I. Kamboh, P. St. George-Hyslop, N. Cairns, J. C. Morris, J. S. K. Kauwe, A. M. Goate, Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature* **505**, 550–554 (2014).
33. L. Mucke, D. J. Selkoe, Neurotoxicity of amyloid β -protein: Synaptic and network dysfunction. *Cold Spring Harb. Perspect. Med.* **2**, a006338 (2012).
34. H. W. Querfurth, F. M. LaFerla, Alzheimer's disease. *N. Engl. J. Med.* **362**, 329–344 (2010).
35. O. A. B. Da Cruz e Silva, S. Rebelo, S. I. Vieira, S. Gandy, E. F. Da Cruz e Silva, P. Greengard, Enhanced generation of Alzheimer's amyloid- β following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C. *J. Neurochem.* **108**, 319–330 (2009).
36. R. F. Lane, J. W. Gatson, S. A. Small, M. E. Ehrlich, S. Gandy, Protein kinase C and rho activated coiled coil protein kinase 2 (ROCK2) modulate Alzheimer's APP metabolism and phosphorylation of the Vps10-domain protein, SorL1. *Mol. Neurodegener.* **5**, 62 (2010).
37. T. Kinouchi, H. Sorimachi, K. Maruyama, K. Mizuno, S. Ohno, S. Ishiura, K. Suzuki, Conventional protein kinase C (PKC)- α and novel PKC ϵ , but not δ , increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts. *FEBS Lett.* **364**, 203–206 (1995).
38. T. Kim, D. J. Hinton, D.-S. Choi, Protein kinase C-regulated $\alpha\beta$ production and clearance. *Int. J. Alzheimers Dis.* 2011, 857368 (2011).
39. K. Tagawa, H. Homma, A. Saito, K. Fujita, X. Chen, S. Imoto, T. Oka, H. Ito, K. Motoki, C. Yoshida, H. Hatsuta, S. Murayama, T. Iwatsubo, S. Miyano, H. Okazawa, Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer's disease brain. *Hum. Mol. Genet.* **24**, 540–558 (2015).
40. D. S. Verbeek, J. Goedhart, L. Bruinsma, R. J. Sinke, E. A. Reits, PKC γ mutations in spinocerebellar ataxia type 14 affect C1 domain accessibility and kinase activity leading to aberrant MAPK signaling. *J. Cell Sci.* **121**, 2339–2349 (2008).
41. H.-. Shi, B. Tang, Y.-W. Liu, X.-F. Wang, G.-J. Chen, Alzheimer disease and cancer risk: A meta-analysis. *J. Cancer Res. Clin. Oncol.* **141**, 485–494 (2015).
42. C. M. Roe, M. I. Behrens, C. Xiong, J. P. Miller, J. C. Morris, Alzheimer disease and cancer. *Neurology* **64**, 895–898 (2005).
43. J. A. Driver, A. Beiser, R. Au, B. E. Kreger, G. L. Splansky, T. Kurth, D. P. Kiel, K. P. Lu, S. Seshadri, P. A. Wolf, Inverse association between cancer and Alzheimer's disease: Results from the Framingham Heart Study. *BMJ* **344**, e1442 (2012).
44. D. Mochly-Rosen, K. Das, K. V. Grimes, Protein kinase C, an elusive therapeutic target? *Nat. Rev. Drug Discov.* **11**, 937–957 (2012).
45. L. Stoppini, P.-A. Buchs, D. Muller, A simple method for organotypic cultures of nervous tissue. *J. Neurosci. Methods* **37**, 173–182 (1991).
46. B. Efron, Bootstrap methods: Another look at the jackknife. *Ann. Stat.* **7**, 1–26 (1979).
47. E. M. Dutil, A. Toker, A. C. Newton, Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1). *Curr. Biol.* **8**, 1366–1375 (1998).
48. M. A. Sherman, S. E. Lesné, Detecting $\alpha\beta$ 56 oligomers in brain tissues. *Methods Mol. Biol.* **670**, 45–56 (2011).
49. L. L. Gallegos, M. T. Kunkel, A. C. Newton, Targeting protein kinase C activity reporter to discrete intracellular regions reveals spatiotemporal differences in agonist-dependent signaling. *J. Biol. Chem.* **281**, 30947–30956 (2006).
50. D. Blacker, L. Bertram, A. J. Saunders, T. J. Moscarillo, M. S. Albert, H. Wiener, R. T. Perry, J. S. Collins, L. E. Harrell, R. C. P. Go, A. Mahoney, T. Beaty, M. D. Fallin, D. Avramopoulos, G. A. Chase, M. F. Folstein, M. G. McInnis, S. S. Bassett, K. J. Doheny, E. W. Pugh, R. E. Tanzi; NIMH Genetics Initiative Alzheimer's Disease Study Group, Results of a high-resolution genome screen of 437 Alzheimer's disease families. *Hum. Mol. Genet.* **12**, 23–32 (2003).
51. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytzky, K. Garimella, D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
52. U. Paila, B. A. Chapman, R. Kirchner, A. R. Quinlan, GEMINI: Integrative exploration of genetic variation and genome annotations. *PLOS Comput. Biol.* **9**, e1003153 (2013).
53. J. Wagner, P. von Matt, R. Sedrani, R. Albert, N. Cooke, C. Ehrhardt, M. Geiser, G. Rummel, W. Stark, A. Strauss, S. W. Cowan-Jacob, C. Beerli, G. Weckbecker, J. P. Evenou, G. Zenke, S. Cottens, Discovery of 3-(1*H*-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. *J. Med. Chem.* **52**, 6193–6196 (2009).

Acknowledgments: We thank L. Gallegos for making the PSD95-CKAR construct, T. Baffi for helping with Fig. 4A, A. Fields for providing PKC α mice, B. Monk for helping in bootstrap analysis, and S. Taylor and A. Kornov for helpful discussions. **Funding:** This work was supported by NIH GM43154 (A.C.N.), NIH MH060009 (R.E.T.), NIH AG032132 (R.M.), GM007752 (C.E.A.), DGE1144086 (C.E.A.), and Cure Alzheimer's Fund (R.E.T., A.C.N., and R.M.). **Author contributions:** S.I.A. conducted electrophysiological experiments; M.A.S. and S.E.L. analyzed expression levels of A β ; J.A.C. and C.E.A. conducted PKC activity experiments and modeling studies; B.H. and K.M. conducted sequence study; M.L. provided PKC α ^{-/-} mice; A.C.N., R.E.T., and R.M. designed the study; and all contributed to writing of the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** All data and materials presented in the study will be made available.

Submitted 3 March 2016
Accepted 22 April 2016
Final Publication 10 May 2016
10.1126/scisignal.aaf6209

Citation: S. I. Alfonso, J. A. Callender, B. Hooli, C. E. Antal, K. Mullin, M. A. Sherman, S. E. Lesné, M. Leitges, A. C. Newton, R. E. Tanzi, R. Malinow, Gain-of-function mutations in protein kinase C α (PKC α) may promote synaptic defects in Alzheimer's disease. *Sci. Signal.* **9**, ra47 (2016).

Gain-of-function mutations in protein kinase C α (PKC α) may promote synaptic defects in Alzheimer's disease

Stephanie I. Alfonso, Julia A. Callender, Basavaraj Hooli, Corina E. Antal, Kristina Mullin, Mathew A. Sherman, Sylvain E. Lesné, Michael Leitges, Alexandra C. Newton, Rudolph E. Tanzi and Roberto Malinow (May 10, 2016)
Science Signaling **9** (427), ra47. [doi: 10.1126/scisignal.aaf6209]

The following resources related to this article are available online at <http://stke.sciencemag.org>.
This information is current as of May 10, 2016.

- Article Tools** Visit the online version of this article to access the personalization and article tools:
<http://stke.sciencemag.org/content/9/427/ra47>
- Supplemental Materials** "*Supplementary Materials*"
<http://stke.sciencemag.org/content/suppl/2016/05/06/9.427.ra47.DC1>
- Related Content** The editors suggest related resources on *Science's* sites:
<http://stke.sciencemag.org/content/sigtrans/8/373/ra39.full>
<http://stke.sciencemag.org/content/sigtrans/7/333/ra66.full>
<http://science.sciencemag.org/content/sci/352/6286/712.full>
<http://stm.sciencemag.org/content/scitransmed/7/309/309ra164.full>
<http://science.sciencemag.org/content/sci/350/6259/430.full>
<http://stke.sciencemag.org/content/sigtrans/9/427/pc11.full>
- References** This article cites 52 articles, 19 of which you can access for free at:
<http://stke.sciencemag.org/content/9/427/ra47#BIBL>
- Permissions** Obtain information about reproducing this article:
<http://www.sciencemag.org/about/permissions.dtl>